No­vo Nordisk con­tin­ues di­a­betes, obe­si­ty sales rise, but still on the back foot with We­govy sup­ply

As de­mand for No­vo Nordisk’s GLP-1 prod­ucts con­tin­ues un­abat­ed, all eyes are on the phar­ma gi­ant to meet de­mand.

Start­ing this month, No­vo has more than dou­bled its starter dos­es for We­govy in the US, which could be re­flect­ed in script num­bers over the next few weeks, CEO Lars Fruer­gaard Jør­gensen said on a me­dia call Wednes­day morn­ing. The com­pa­ny be­gan re­strict­ing starter dos­es in May.

But sup­ply re­mains un­steady, as We­govy sup­ply is­sues con­tin­ue due to un­wa­ver­ing de­mand. Ac­cord­ing to the FDA, it is still in short­age in the US. “It’s prob­a­bly to be ex­pect­ed that for quite some time. There’ll be a de­mand that out­grows what can be pro­duced by us and prob­a­bly al­so com­pe­ti­tion,” Jør­gensen said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER